NeuralBot system receives US FDA clearance


Neural Analytics has announced that it has received US Food and Drug Administration (FDA) 510(k) clearance for its NeuralBot System, a robotic assistance technology which automatically adjusts orientation and position of its ultrasound products under the guidance of a healthcare professional. When used with its previously cleared Lucid M1 Transcranial Doppler Ultrasound System, can assist clinicians to non-invasively monitor a patient’s brain blood flow characteristics and can provide information to diagnose a variety of neurological disorders.

“Progress in treating neurological disorders has lagged due to a lack of available low-cost and objective patient diagnostic information. This has resulted in misdiagnosis, treatment delays and additional healthcare expenditures for patients suffering neurological disease,” said Robert Hamilton, co-founder and chief scientific officer of Neural Analytics. “Our new technology can assist a healthcare professional- when an expert technician is not available – with the collection of blood flow data to assist clinicians in efficiently triaging patients for appropriate treatment.”

Recently, Neural Analytics presented research data that demonstrated there was no statistical difference between ultrasound blood flow data collected with its NeuralBot System or data collected manually by an expert technician with its traditional ultrasound platform.

“We are committed to advancing brain healthcare through transformative technology that empowers neurologists with the critical information needed to make clinical decisions and improve patient outcomes,” said Leo Petrossian, co-founder and chief executive officer of Neural Analytics. “Our products provide clinicians with a cost effective and non-invasive assessment of a patient’s brain health, and can help clinicians diagnose brain disorders, potentially without the need for more invasive testing.”

Neural Analytics will immediately commercialise the NeuralBot system with its currently available Lucid M1 TCD System in the US as the ‘Lucid Robotic System.’ The Lucid Robotic System, when used for a transcranial doppler ultrasound procedure for patients suspected of neurological disorder, is reimbursable by Medicare/Medicaid and most private payers.



Please enter your comment!
Please enter your name here